| CGS CIMB |
CGS CIMB |
|
Grand Venture Technology Ltd GVT guides 1H24F revenue of S$58m-64m
■ FY23 revenue of S$111.3m (-15.1% yoy) was 3.0%/2.0% above our/Bloomberg consensus’ forecasts. ■ FY23 net profit of S$5.5m (-58.4% yoy) was 2.7%/5.2% below our/Bloomberg consensus’ forecasts. ■ Reiterate Add (unchanged S$0.62 TP) as we expect the semicon industry recovery to drive GVT’s net profit recovery over FY24-26F.
|
Seatrium Ltd Scrubbed clean, overhang removed
■ Brazilian litigation overhang on STM has been largely removed. It reached an in-principal agreement with authorities with S$265m provisions made. ■ S$1.795bn of provisions were made in 2H23 for write-down of non-core asset surplus, closure of yards, onerous contracts and Brazilian settlement. ■ We estimate 2H23 core GM at 3-5%, on +53% hoh in turnover to S$4.4bn. ■ Catalysts: order wins, improvement in margins. Risks: project cost overrun. Reiterate Add but reduce TP to S$0.14 (still 1.4x P/BV, reflecting FY23 BV).
|
|
CGS CIMB |
UOB KAYHIAN |
|
Credit Bureau Asia Ltd Bulk risk reviews still in demand
■ 2H23 PATMI of S$5.1m was above our expectation. CBA declared a final DPS of 2Scts; full-year DPS of 3.7Scts represents an 87% payout ratio. ■ The PATMI beat was due to strong uptake of risk review reports in its FI data business. Non-FI segment was steady, with more enquiries from SG and MY. ■ Reiterate Add. Improving regional GDP growth should lift its credit enquiry volumes as the elevated interest rate environment sustains bulk risk reviews.
|
Raffles Medical Group (RFMD SP) 2023: Weaker Margins in Line With Expectations; Headwinds Persist
RFMD reported sharply lower PATMI of S$90.2m (-37.1% yoy) but was in line with expectations. The hospital operations reported a robust performance driven by increased patient intake and cost pass-through, offset by the impact of the strong Singapore dollar. Healthcare services segment suffered from lack of COVID-19-related revenue but is likely to stabilise in 2024. RFMD’s China operations continue to perform better as patient load ramps up. Maintain HOLD with the same target price of S$1.15.
|
| UOB KAYHIAN | |
|
Seatrium (STM SP) 2023: Underying EBITDA And Profit Are Encouraging
Material one-off non-cash write-downs led to the attention-grabbing loss of S$1.9b for 2023; however, we highlight that the company’s underlying EBITDA rose fivefold to S$628m with a positive trend since 1H22. Importantly, STM made a net profit of S$33m in 2H23 indicating that profitability is around the corner. The company has proposed a 20-for-1 share consolidation to be approved at its upcoming AGM. Maintain BUY. Target price lowered to S$0.151.
|
